Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas

Award Number: R50CA275929
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/06/2023
PERIOD OF PERFORMANCE END DATE: 02/29/2028

Group Awards By:

View Award Description

Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas - Deborah Stephens, DO is an Associate Professor at the Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina (UNC) who focuses on evaluation of novel targeted agents and combination therapies in patients with chronic lymphocytic leukemia (CLL) and B-cell lymphomas with the ultimate goal of improving clinical care and outcomes. The scope of her clinical trials program [including National Cancer Institute (NCI)-sponsored, investigator-initiated, and industry-sponsored trials] is significant as it improves the care not only for local patients but has also produced research outcomes leading to changes in the standard of care for patients. Through several national and local leadership roles, Dr. Stephens dedicates 75% of her time to research. At UNC, she serves in the roles of Director of the CLL and Lymphoma Research Program and as a Co-Program Leader for the UNC LCCC Cancer Therapeutics Program. Specifically, 40% of her total time will continue to focus on NCI-sponsored clinical trials, which is solely supported by the R50 Research Specialist Award. Her R50-related activities include: (1) her role as international principal investigator for the S1925 EVOLVE CLL Trial (NCT04269902; 15% effort); (2) her role as CLL Lead for the SWOG Leukemia Working Group (10% effort), where she organizes a task force of other CLL specialists to develop SWOG CLL clinical trials. In this role, she will also serve as a mentor and co-investigator on S2504 PIRAMID Trial for Richter Transformation (NCT07220187) and is mentoring a junior faculty to open an additional SWOG CLL trial for patients with relapsed disease. She will be author on the recently completed ECOG and Alliance CLL clinical trials (NCT03701282 and NCT03737981). She meets monthly with CLL leaders from ECOG and Alliance to discuss trial issues and plan next studies and participates in bi-annual SWOG meetings; (3) her role as an active member of the SWOG Lymphoma Working Group (10% effort), where she continues to perform research on data from the S1001 (NCT01359592) and S0816 (NCT00822120) clinical trials and her role mentoring Dr. Boyu Hu who is the adult chair for AHOD2131 and will chair S2506; (4) and her role as Experimental Therapeutics Clinical Trials Network (ETCTN) hematology expert for LCCC’s UM1 grant with The Ohio State University as Lead Academic Organization UM1-CA186712 (Carson), where she works alongside Dr. Claire Dees (Medical Oncology) to represent UNC. (Her effort related to UNC’s ETCTN Group is 10%, with this R50 grant to continue funding 5% of this effort.) As such, continued support from this R50 Grant, allows Dr. Stephens to continue her work and plans for meeting the objectives of the NCI-funded clinical trials research program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $151,525 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	5	3/3/2026	NON-COMPETING CONTINUATION	$151,525
														Subtotal = $151,525

Issue Date FY: 2025 ( Subtotal = $168,361 )
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	001	4	2/28/2025	NON-COMPETING CONTINUATION	$168,361
2025	2023	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Cause and Prevention Research	000	1	2/14/2025	NEW	$0
														Subtotal = $168,361

Issue Date FY: 2024 ( Subtotal = $168,360 )
2024	2024	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	002	3	2/7/2024	NON-COMPETING CONTINUATION	$168,361
2024	2023	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Cause and Prevention Research	000	1	1/11/2024	NEW	-$84,302
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	001	2	1/11/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$84,301
														Subtotal = $168,360

Issue Date FY: 2023 ( Subtotal = $168,132 )
2023	2023	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Cancer Cause and Prevention Research	000	1	3/6/2023	NEW	$168,132
														Subtotal = $168,132

Grand Total All Awards = $656,378

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas

Award Number: R50CA275929

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/06/2023

PERIOD OF PERFORMANCE END DATE: 02/29/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer